Jamie J. Newman
Massachusetts Institute of Technology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jamie J. Newman.
Cell | 2008
Alexander Marson; Stuart S. Levine; Megan F. Cole; Garrett M. Frampton; Tobias Brambrink; Sarah E. Johnstone; Matthew G. Guenther; Wendy K. Johnston; Marius Wernig; Jamie J. Newman; J. Mauro Calabrese; Lucas M. Dennis; Thomas L. Volkert; Sumeet Gupta; Jennifer Love; Nancy M. Hannett; Phillip A. Sharp; David P. Bartel; Rudolf Jaenisch; Richard A. Young
MicroRNAs (miRNAs) are crucial for normal embryonic stem (ES) cell self-renewal and cellular differentiation, but how miRNA gene expression is controlled by the key transcriptional regulators of ES cells has not been established. We describe here the transcriptional regulatory circuitry of ES cells that incorporates protein-coding and miRNA genes based on high-resolution ChIP-seq data, systematic identification of miRNA promoters, and quantitative sequencing of short transcripts in multiple cell types. We find that the key ES cell transcription factors are associated with promoters for miRNAs that are preferentially expressed in ES cells and with promoters for a set of silent miRNA genes. This silent set of miRNA genes is co-occupied by Polycomb group proteins in ES cells and shows tissue-specific expression in differentiated cells. These data reveal how key ES cell transcription factors promote the ES cell miRNA expression program and integrate miRNAs into the regulatory circuitry controlling ES cell identity.
Cell | 2008
Andrea Ventura; Amanda G. Young; Monte M. Winslow; Laura Lintault; Alexander Meissner; Stefan J. Erkeland; Jamie J. Newman; Roderick T. Bronson; Denise Crowley; James R. Stone; Rudolf Jaenisch; Phillip A. Sharp; Tyler Jacks
miR-17 approximately 92, miR-106b approximately 25, and miR-106a approximately 363 belong to a family of highly conserved miRNA clusters. Amplification and overexpression of miR-1792 is observed in human cancers, and its oncogenic properties have been confirmed in a mouse model of B cell lymphoma. Here we show that mice deficient for miR-17 approximately 92 die shortly after birth with lung hypoplasia and a ventricular septal defect. The miR-17 approximately 92 cluster is also essential for B cell development. Absence of miR-17 approximately 92 leads to increased levels of the proapoptotic protein Bim and inhibits B cell development at the pro-B to pre-B transition. Furthermore, while ablation of miR-106b approximately 25 or miR-106a approximately 363 has no obvious phenotypic consequences, compound mutant embryos lacking both miR-106b approximately 25 and miR-17 approximately 92 die at midgestation. These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functions during B lymphopoiesis and lung development.
Nature | 2007
Andrea Ventura; David G. Kirsch; Margaret McLaughlin; David A. Tuveson; Jan Grimm; Laura Lintault; Jamie J. Newman; Elizabeth E. Reczek; Ralph Weissleder; Tyler Jacks
Tumorigenesis is a multi-step process that requires activation of oncogenes and inactivation of tumour suppressor genes. Mouse models of human cancers have recently demonstrated that continuous expression of a dominantly acting oncogene (for example, Hras, Kras and Myc) is often required for tumour maintenance; this phenotype is referred to as oncogene addiction. This concept has received clinical validation by the development of active anticancer drugs that specifically inhibit the function of oncoproteins such as BCR-ABL, c-KIT and EGFR. Identifying additional gene mutations that are required for tumour maintenance may therefore yield clinically useful targets for new cancer therapies. Although loss of p53 function is a common feature of human cancers, it is not known whether sustained inactivation of this or other tumour suppressor pathways is required for tumour maintenance. To explore this issue, we developed a Cre-loxP-based strategy to temporally control tumour suppressor gene expression in vivo. Here we show that restoring endogenous p53 expression leads to regression of autochthonous lymphomas and sarcomas in mice without affecting normal tissues. The mechanism responsible for tumour regression is dependent on the tumour type, with the main consequence of p53 restoration being apoptosis in lymphomas and suppression of cell growth with features of cellular senescence in sarcomas. These results support efforts to treat human cancers by way of pharmacological reactivation of p53.
Nature | 2010
Michael H. Kagey; Jamie J. Newman; Steve Bilodeau; Ye Zhan; David A. Orlando; Nynke L. van Berkum; Christopher C. Ebmeier; Jesse Goossens; Peter B. Rahl; Stuart S. Levine; Dylan J. Taatjes; Job Dekker; Richard A. Young
Transcription factors control cell-specific gene expression programs through interactions with diverse coactivators and the transcription apparatus. Gene activation may involve DNA loop formation between enhancer-bound transcription factors and the transcription apparatus at the core promoter, but this process is not well understood. Here we report that mediator and cohesin physically and functionally connect the enhancers and core promoters of active genes in murine embryonic stem cells. Mediator, a transcriptional coactivator, forms a complex with cohesin, which can form rings that connect two DNA segments. The cohesin-loading factor Nipbl is associated with mediator–cohesin complexes, providing a means to load cohesin at promoters. DNA looping is observed between the enhancers and promoters occupied by mediator and cohesin. Mediator and cohesin co-occupy different promoters in different cells, thus generating cell-type-specific DNA loops linked to the gene expression program of each cell.
Genes & Development | 2008
Megan F. Cole; Sarah E. Johnstone; Jamie J. Newman; Michael H. Kagey; Richard A. Young
Embryonic stem (ES) cells have a unique regulatory circuitry, largely controlled by the transcription factors Oct4, Sox2, and Nanog, which generates a gene expression program necessary for pluripotency and self-renewal. How external signals connect to this regulatory circuitry to influence ES cell fate is not known. We report here that a terminal component of the canonical Wnt pathway in ES cells, the transcription factor T-cell factor-3 (Tcf3), co-occupies promoters throughout the genome in association with the pluripotency regulators Oct4 and Nanog. Thus, Tcf3 is an integral component of the core regulatory circuitry of ES cells, which includes an autoregulatory loop involving the pluripotency regulators. Both Tcf3 depletion and Wnt pathway activation cause increased expression of Oct4, Nanog, and other pluripotency factors and produce ES cells that are refractory to differentiation. Our results suggest that the Wnt pathway, through Tcf3, brings developmental signals directly to the core regulatory circuitry of ES cells to influence the balance between pluripotency and differentiation.
Cancer Cell | 2005
Elsa R. Flores; Shomit Sengupta; John B. Miller; Jamie J. Newman; Roderick T. Bronson; Denise Crowley; Annie Yang; Frank McKeon; Tyler Jacks
Nature | 2011
Michael H. Kagey; Jamie J. Newman; Steve Bilodeau; Ye Zhan; David A. Orlando; Nynke L. van Berkum; Christopher C. Ebmeier; Jesse Goossens; Peter B. Rahl; Stuart S. Levine; Dylan J. Taatjes; Job Dekker; Richard A. Young
Gastroenterology | 2011
Alan C. Mullen; Jamie J. Newman; David A. Orlando; Richard A. Young
Elsevier | 2011
Alan C. Mullen; David A. Orlando; Jamie J. Newman; Jakob Lovén; Roshan M. Kumar; Steve Bilodeau; Jessica Reddy; Matthew G. Guenther; Rodney P. DeKoter; Richard A. Young
Gastroenterology | 2010
Alan C. Mullen; Jamie J. Newman; Roshan M. Kumar; David A. Orlando; Richard A. Young